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Abstract
Hereditary hearing loss is a very heterogeneous trait, with 46 gene identifications for nonsyndromic
hearing loss. Mutations in GJB2 cause up to half of all cases of severe-to-profound congenital
autosomal recessive nonsyndromic hearing loss, with 35delG being the most frequent mutation in
Caucasians. Although a genotype-phenotype correlation has been established for most GJB2
genotypes, the hearing loss of 35delG homozygous patients is mild-to-profound. We hypothesize
that this phenotypic variability is at least partly caused by the influence of modifier genes. By
performing a whole-genome association study on 35delG homozygotes, we sought to identify
modifier genes. The association study was performed by comparing the genotypes of mild/moderate
cases and profound cases. The first analysis included a pooling-based whole-genome association
study of a first set of 255 samples by using both the Illumina 550K and Affymetrix 500K chips. This
analysis resulted in a ranking of all analysed SNPs according to their p-values. The top 250 most
significantly associated SNPs were genotyped individually in the same sample set. All 192 SNPs
that still had significant p-values were genotyped in a second independent set of 297 samples for
replication. The significant p-values were replicated in nine SNPs, with combined p-values between
3×10−3 and 1×10−4. This study suggests that the phenotypic variability in 35delG homozygous
patients cannot be explained by the effect of one major modifier gene. Significantly associated SNPs
may reflect a small modifying effect on the phenotype. Increasing the power of the study will be of
the greatest importance to confirm these results.
Keywords
Hereditary hearing loss; connexin 26; 35delG; association study; modifier gene
INTRODUCTION
Hearing loss (HL) is the most common birth defect in industrialised countries and also the most
frequent sensorineural disorder, affecting about 1/500 newborns.1 The causes of HL are diverse
but a genetic defect can be found in at least 50% of cases. The identification of deafness genes
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for hereditary HL has evolved very quickly during the past 10 years, with 46 different genes
known to cause nonsyndromic hearing impairment (Hereditary Hearing Loss Homepage:
http://webh01.ua.ac.be/hhh/). This large number of deafness genes makes HL a very
heterogeneous trait, with most genes being causative in only a small percentage of patients.
However, the GJB2 gene (gap junction protein beta-2 encoding for connexin 26) is responsible
for up to 50% of cases with autosomal recessive nonsyndromic sensorineural hearing loss
(ARNSHL).2
Mutations in GJB2 are the most frequent cause of ARNSHL and according to the connexin-
deafness homepage, over 100 different mutations have been identified
(http://davinci.crg.es/deafness/index.php). GJB2 mutations also cause autosomal dominant
HL, often in combination with skin disorders. While most mutations are not very frequent,
35delG has been found in over 50% of Caucasians with GJB2 mutations. Carrier frequencies
in Europe range from 0.5% to 3.5% with the highest frequencies found in the Mediterranean
regions.3 A large multicenter study has established genotype-phenotype correlations for
connexin 26-related HL, based on audiometric data of 1531 patients from 26 laboratories.4 All
patients suffered from nonsyndromic mild-to-profound HL due to biallelic GJB2 mutations.
The study clearly demonstrated that inactivating mutations of GJB2 cause a more severe
phenotype than non-inactivating mutations. In addition, mutations M34T and V37I were shown
to cause a mild HL when in compound heterozygosity with an inactivating mutation. Although
specific genotype-phenotype correlations were established for most genotypes, the correlation
could only explain part of the phenotypic variability. For most genotypes, a certain degree of
variation was still present, which was mostly pronounced within the group of patients with a
homozygous 35delG genotype. Both inter- and intrafamilial variation were observed, with the
HL ranging from mild or moderate (least often) to severe and profound (most frequent). This
phenotypic variation may be explained by the influence of environmental factors and/or by the
influence of modifier genes.
Several strategies can be used to identify modifier genes for human disorders. In mice, the
identification can be performed by crossing parental inbred strains that carry the disease-
causing mutation and exhibit a difference in phenotype. Two examples are the modifier gene
Mdfw in deafwaddler mice with an Atp2b2-mutation5 and the modifier gene Moth1 in the Tubby
mouse.6 There is however a limitation in available inbred strains and some mouse mutants are
not an accurate model for the human phenotype. In addition, Gjb2 knockout mice are embryonic
lethal.7 Using human patients, two strategies can be adopted. The first approach uses families
and linkage analysis. A whole genome search is performed to investigate the phenotypic
difference among patients from multiplex families with sufficient intrafamilial variation. In
this way, the DFNM1 locus was identified as a modifier of DFNB26-linked HL and the
1555A>G mutation in MTRNR1 was shown to be modified by three different genes: MTO1,
TFB1M and GTPBP3.8 The second strategy uses association studies in unrelated patients. Here,
the correlation between the phenotypic variation and genetic markers is analysed statistically.
The development of SNP chips by Illumina and Affymetrix containing hundreds of thousands
of SNPs covering the complete genome makes these whole-genome association (WGA) studies
possible. Associated genetic factors involved in complex diseases are identified in a
hypothesis-free way. However, WGA studies for individual samples are costly. An alternative
strategy is to use pooled genomic DNA. The Research Institute TGen (Translational Genomics
Research Institute, Phoenix, Arizona, USA) has developed a pooling-based WGA approach
which is of high quality and has been proven successful in the identification of important
associations for complex traits.9–13 An important note is that pooling-based WGA studies are
only effective in identifying common variations with a large effect on the disease.
In this report, we sought to identify modifier genes for connexin 26-related hearing impairment
by performing a WGA with pooled DNA samples in a set of 35delG homozygous patients.
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The population is suitable for identifying modifier genes because it is a genetically
homogeneous sample set, eliminating the effect of the mutation on the phenotype as a
confounding factor. The 35delG mutation is very common in Caucasians, making it possible
to collect a relatively large sample set. Characterizing modifier genes for GJB2 is important
for several reasons. First, it could lead to improved diagnosis and genetic counselling by
facilitating a more accurate prediction of the phenotype based on the genotype of both GJB2
and the modifier gene. Second, it could provide a better definition of the auditory pathways in
which the primary mutation functions and gain potentially novel insights into the molecular
pathology of HL. Finally, knowledge of modifiers may allow the development of new therapies
making GJB2-related deafness more amenable to treatment.
MATERIALS AND METHODS
Sample and data collection
The study was approved by the ethical committee of the University of Antwerp and by the
ethical committees of all research institutes collaborating in this study. Informed consent was
obtained by each research centre from every participant or from the parents of minors. For
every patient, a series of data were collected, including general data (e.g. date of birth, gender,
ethnicity and the presence of additional clinical features apart from the hearing loss) and
audiometric data (age of onset, date of audiometry, audiometric technique used and hearing
thresholds). In addition, a DNA sample of good quality of the 35delG homozygous patient was
collected. These data were used to select the appropriate samples. In total, 25 centres from 14
different countries across Europe and North America collaborated in this study. This strategy
resulted in the collection of 1277 unrelated samples with a clear excess of patients with
profound hearing loss (Figure 1). The sample set consisted solely of unrelated samples to avoid
bias. Names were not used to identify any of the samples to guarantee anonymity of the patients.
Audiometric data were obtained by use of different techniques. In most cases, hearing levels
were obtained by pure tone audiometry (PTA) by making measurements at frequencies ranging
from 0.125 kHz to 8 kHz. A few centres also used other techniques apart from PTA, in most
cases to obtain hearing thresholds in very young children. On the one hand, electrical responses
to sound were measured by use of automated brainstem response, steady-state evoked
potentials, auditory steady-state response and electrocochleogram. On the other hand and in a
minority of cases, two behavioural tests, visual reinforcement audiometry and conditioned
orientation reflex, were used for measuring the hearing thresholds.
To verify the 35delG genotype in all samples obtained, the Snapshot (Applied Biosystems)
detection method was used according to the manufacturer’s instructions. The samples were
analysed with an ABI PRISM 3100 Genetic analyzer (Applied Biosystems). Samples with an
unclear Snapshot result were analysed by DNA sequencing to determine the correct genotype.
Study design
The identification of modifier genes was performed using a pooling-based WGA study in a
35delG homozygous patient cohort.10 The PTA0.5,1,2kHz was the variable under investigation
and was used to create a ‘case’ and ‘control’ group of patients, only using the two extremes of
the PTA spectrum. As the sample set consisted of patients with 14 different nationalities, we
chose to match the samples for ethnicity, based on the centre where the samples originated
from. Within each ethnicity, patients were divided into a mild/moderate group (the ‘case’
group) and a profound group (the ‘control’ group), based upon their PTA0.5,1,2kHz. To create
the mild/moderate group, all mild and moderate cases with a PTA0.5,1,2kHz ≤70 dB within each
ethnicity were selected. To create the profound group, each sample of the mild/moderate group
was matched to two samples from the profound group with a PTA0.5,1,2kHz ≥100 dB from the
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same ethnicity. Using this approach, every sample from the mild/moderate group had two
ethnically matched samples from the profound group, making the profound group twice as
large as the mild/moderate group.
The WGA was designed in three stages: 1. Pooling-based WGA on mild/moderate and
profound pools from the first sample set, analysed on two SNP chips; 2. Individual genotyping
of the top 250 most significantly associated SNPs in the same sample set; 3. Individual
genotyping of the significant SNPs in an independent replication population.
Creating DNA pools for WGA
The WGA study on pooled DNA was performed in an initial sample set of 255 samples. Before
quantification, all DNA samples were loaded on a 1.5% agarose gel to exclude degraded
samples from the pooling analysis. Genomic DNA concentrations of all samples were
measured in triplicate with the QuantiT PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad,
California) according to the manufacturer’s instructions. The median concentration was
calculated for each sample and was used to determine the volume of DNA needed in the DNA
pool to obtain equivalent molar amounts. 85 samples from the mild/moderate group were
pooled, as well as 170 samples from the profound group. To control for pipetting errors, the
pools were created in quadruplicate to have microarray technical replicates, providing eight
individual ethnically matched pools. Through these replicates, variance arising from pooled
allelotyping can be measured and a quality control can be provided to eliminate poorly
performing SNPs and failed assays.
Genotyping with Illumina and Affymetrix chips
The WGA analysis of the first sample set of 35delG homozygous samples was done using two
different SNP chips: the Sentrix®humanhap550 genotyping beadchip (Illumina, San Diego,
USA), containing 555,000 tag SNPs and the Affymetrix 500K chip (Affymetrix, Santa Clara,
CA, USA) containing 500,000 SNPs with an average distance of 5.8 kb. For both SNP chips,
the pools were assayed in four technical replicates following the protocols for individual
genotyping for both platforms. Combining the two genotyping platforms leaves only a few
gaps in the overall genome-wide SNP coverage, reducing the number of genomic regions that
are not analysed.10
The first step in the data analysis was scoring and ranking the SNPs from both Illumina and
Affymetrix platforms separately, based on GenePool silhouette scores.10 The top 5000 SNPs
of both platforms was taken along for calculation of allele frequencies. The allele frequencies
were inferred from the pool data using k-correction factors and subsequently, t-test p-values
were calculated. The SNPs were then sorted according to the allele frequency based p-values.
The k-correction method was used to estimate the pooling accuracy as described by Craig et
al.9 SNPs with a k-correction factor below 0.5, above 2 and exactly 1 were not analyzed further
because their estimation of allele frequencies was deemed not reliable enough. In addition,
SNPs with minor allele frequencies less than 3% according to Hapmap were excluded, as well
as the top 1% most variable SNPs. A final selection of 250 SNPs from both platforms was
taken forward for individual genotyping. No multiple testing correction was performed to make
the SNP selection.
Individual genotyping
The selected 250 SNPs from both platforms were individually genotyped in the same sample
set by Kbioscience (Hoddesdon, UK), using the KASPar SNP genotyping chemistry. The data
analysis and quality control was performed in SAS (SAS 9.1.2; SAS Institute Inc., Cary, NC,
USA). First, several quality checking steps were performed. Samples with more than 15%
missing genotyping data were excluded. Next, the percentage of missing data per SNP was
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calculated and SNPs with more than 3% missing genotypes were excluded. Hidden relatives
were removed from further analysis with GRR (Graphical Relationship Representation).14
Checkhet was used to look for genetically abnormal samples per ethnicity, based on genotypes
of multiple SNPs.15 Finally, the Hardy Weinberg Equilibrium was checked per ethnicity and
SNPs with a p-value below 0.001 were also excluded. For the statistical analysis, p-values and
allelic odds ratios were calculated for each SNP with the Armitage’s Trend Test by use of the
statistical software program R (www.r-project.org). This trend test uses an additive model,
which has been proven successful for the detection of additive and dominant disease
susceptibility loci.16
In a next step, individual genotyping of the significant SNPs from the previous genotyping was
performed in an independent replication population to confirm their significance. A replication
set of 297 samples was collected, containing 99 mild/moderate samples and 198 profound
samples. The same quality control and statistical analysis was performed as for the individual
genotyping in the first sample set. A combined p-value for SNPs that were significant in both
sample sets was obtained with the Mantel-Haenszel test. This test measures the strength of
association by estimating the common odds ratio. A significant interaction p-value indicates a
different effect of the genotype on the phenotype in the two sample sets. If the interaction term
is not significant, a common odds ratio and a combined p-value can be calculated using Mantel-
Haenszel statistics.
For genes that were in linkage disequilibrium with a significantly associated SNP, their
expression in the cochlea was checked on the basis of the Morton human fetal cochlear EST
database (http://www.brighamandwomens.org/bwh_hearing/human-cochlear-ests.aspx) and
the Unigene-database (http://www.ncbi.nlm.nih.gov/).
RESULTS
Pooling-based WGA
The pooling based WGA study was performed on a first set of 255 samples (85 mild/moderate
samples and 170 profound samples) on both the Illumina and Affymetrix platform. The analysis
of the genotyping data resulted in a ranking of SNPs for both platforms separately, according
to the allele frequency based p-values. For each SNP in the top 250, its position was evaluated
in relation to the neighbouring genes. Only SNPs in proximity to a gene were selected. SNPs
that were not in linkage disequilibrium (LD) with any genes in a region of 500 kb upstream
and downstream of the gene were excluded. If two SNPs were in complete LD with each other,
only one of them was included in the selection. As the Illumina chip provides higher quality
data than the Affymetrix chip with regards to variance measurements, more Illumina SNPs
were taken along.17 In this way, 155 Illumina SNPs and 95 Affymetrix SNPs were selected
for further analysis.
The 250 selected SNPs were individually genotyped in the same sample set. Quality control
resulted in the exclusion of 21 samples and 14 SNPs. The Armitage’s Trend Test was performed
for 236 SNPs in 234 35delG homozygous samples. P-values ranged between 1.48.10−6 and
0.68. 198 SNPs had p-values below 0.05 and were subsequently genotyped in the replication
set.
The replication population was collected in the same way as the first sample set. Genotyping
analysis was performed for those 198 SNPs that were significant in the first set, in 297 samples
(99 mild/moderate samples and 198 profound samples). The quality check resulted in the
exclusion of 27 samples and 6 SNPs. Subsequently, 192 SNPs were statistically analysed by
the Armitage’s Trend Test in 270 samples. 12 SNP’s out of 192 still showed significant p-
values in the replication population and are listed in Table 1. The Mantel Haenszel test was
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used to calculate the interaction term and if allowed, the combined p-values and odds ratios
for the complete sample set. Three SNPs had a significant interaction p-value and the odds
ratios of both independent sample sets indicated an opposite effect. The remaining 9 SNPs all
had the same effect on the phenotype and had combined p-values between 1×10−5 and
3×10−4 and combined odds ratios between 0.38 and 1.88 (Table 1).
Candidate genes
Eleven genes were found to be in linkage disequilibrium with the significantly associated SNPs
in both populations. SNP rs2215128 was in LD with 5 different genes and two of them,
RPS23 and ATG10, were expressed in the cochlea according to the Morton human fetal cochlear
EST database and/or Unigene. All other genes in LD with one of the nine SNPs were not
expressed in the cochlea (Table 2).
DISCUSSION
In this study, we sought to identify modifier genes for connexin 26-related hearing impairment
in a set of 1277 35delG homozygous patients from 14 countries. As they share the same
homozygous mutation, phenotypic variation on the basis of the mutation is already excluded.
Figure 1 shows the excess of profound cases compared to mild and moderate cases. As the
distribution of samples in the different hearing loss categories is not normally distributed, we
chose not to study the PTA0.5,1,2kHz as a quantitative trait. Instead, we chose to work under a
case-control paradigm by selecting the two extreme spectra of the curve. However, as a
consequence, we were restricted in the total number of cases for analysis given the limited
number of mild/moderate cases. We had to compromise between on the one hand, having a
large enough power by analysing enough samples and on the other hand, selecting mild/
moderate cases and profound cases from the two spectra for which the PTA0.5,1,2kHz values
showed a difference that was large enough. Therefore, we chose cut-off values of 70 dB and
100 dB for the mild/moderate and profound group, respectively.
In order to pick up modifier genes for connexin 26, we chose to perform a WGA as the genetic
pathways in which connexin 26 functions are only partly understood, making it difficult to
select candidate genes. Pooled WGA studies are a very good and cost-effective alternative to
detect common variants with a large effect on the phenotype. Finding true associations can
only be achieved when a number of requirements are fulfilled. A number of parameters need
to be of sufficient size, including the allele frequency of the causal variant, the LD between
the causal variant and the typed SNPs, the odds ratio and the sample size. In addition, several
extra factors need to be taken into account when pooling is used. We tried to solve most of
these issues as discussed by Pearson et al.10 For example, the DNA concentrations were
measured in triplicate, degraded DNA samples were excluded and pools were constructed in
quadruplicate. Population stratification and admixture have largely been excluded by matching
all mild/moderate and profound samples per ethnicity. As pooling-based WGA studies are
much more affordable, we were able to use both the Illumina 550K and the Affymetrix 500K
platforms, typing about 800,000 different SNPs without leaving large gaps in the genome. A
quality control for the accuracy of the pooling phase in pooling-based WGA studies is the
number of significant associations that still remain after individual genotyping of the top 250
SNPs of the pooled analysis. In our study, 198 out of 236 successfully genotyped SNPs had a
p-value below 0.05, which corresponds to 84%. This is a high percentage, indicating that the
allele frequencies on the basis of the pooled data are reasonably accurate.
A few issues however remain. The major restriction of pooling-based WGAs is the ability to
only detect large effects. A first reason for this is the problem to reach a very high accuracy of
allele frequency measurements. As the measurement error is usually around 2%, it becomes
more difficult to accurately rank the SNPs after pooling. Secondly, you loose the ability to
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compare subphenotypes of pools to directly measure genotypes and detect gene-gene
interactions. The number of individuals pooled in this study was not very high, but as discussed
before, our study design was chosen very carefully and major efforts were done to collect a
large amount of samples.
The results from the genome-wide associations study do not show a very strong association in
the population we studied. This observation may suggest that the phenotypic variability in
35delG homozygous patients cannot be explained by the effect of one major modifier gene. If
this would have been the case, we should have picked up this gene in the current study, despite
the pooling strategy and the restricted number of samples we have. The SNPs that were
significantly associated in both populations tested may have a small modifying effect. For two
cochlear expressed genes, RPS23 and ATG10, an associated SNP was found in LD.
RPS23 encodes for the ribosomal protein S23, which is related to S. cerevisiae ribosomal
protein S28. RPS23 belongs to the small 40S subunit of the ribosomes. Although the gene is
ubiquitously expressed, the highest number of ESTs is found in the ear and 26 ESTs of
RPS23 were present in the Morton database. In addition, the gene was found in a human
vestibular cDNA library.18 The expression in both the cochlea and vestibular system might
indicate a special role for RPS23 in the auditory and vestibular function. No direct link between
RPS23 and GJB2 could be found in the literature.
ATG10 encodes for the autophagy related 10 homolog of the yeast S. cerevisiae. Its protein
ATG10 is an E2-like enzyme involved in autophagy, a cellular mechanism for bulk degradation
of cellular proteins and organelles in lysosomes.19 Although many E2 enzymes have been
identified in eukaryotes, including the ubiquitin-conjugating enzyme family (Ubc), ATG10
does not show any homology to other known E2 enzymes.20 The gene is not present in the
Morton database but according to the Unigene expression profile, it is expressed in the ear. No
known function in the hearing process has been reported for ATG10.
The other candidate genes in LD with significantly associated SNPs can also not be ruled out
as modifier genes. Their lack of expression in the cochlea according to the Morton database
and Unigene does not completely rule out their presence in the ear. SNPs that are not in
immediate LD with a gene may also have a modifying effect for example by being located in
cis-acting elements which control the expression of more distant genes. Libioulle et al (2007)
found a possible association between Crohn disease and a SNP in a gene desert. This SNP is
located 270kb from the closest gene PTGER4 and was found to regulate the expression level
of this gene, suggesting its involvement in Crohn disease.21
In the future, there are several options to extend this study. On the one hand, RPS23 and
ATG10 could be good candidate modifiers with a smaller effect on the phenotype as they are
expressed in the human cochlea. Finemapping of the region around rs2215128 should be the
first step in confirming the association. Further on, functional research may be performed to
elucidate the specific role of RPS23 and ATG10 in the hearing process and link them to
connexin 26. It may also be interesting to look for cis-acting elements in the regions around
the significantly associated SNPs to identify effects on genes at larger distance. In this regard,
it may also be of interest to individually genotype SNPs from the top 250 of the pooling
experiment which are not in LD with a nearby gene. One of the most important aims should
be to increase the power of the study. This could mainly be done by collecting additional
samples. The current sample set was collected by 25 centres across Europe and North America.
We are convinced that it should be possible to collect additional samples from more centres,
as diagnostic testing of GJB2 is widespread and 35delG homozygous patients are very
frequently picked up. We hope to find additional contributors in the future to extend this study.
Another way to increase the power is by genotyping all collected samples on individual SNP
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chips. This strategy has the major advantage of having separate and accurate genotyping data
for all samples and gives the opportunity to look for gene-gene interactions. These interactions
might be of great importance for this study. As the results of this study suggest that no major
modifier gene is present, we assume that the phenotypic variation will be caused by a smaller
effect of different interacting genes.
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Figure 1.
Phenotypic variability of 35delG homozygous patients. All 1277 samples were grouped in
categories of 5 dB ranges and were put in a graph to show the spread of the hearing loss in
these patients. Hearing thresholds were obtained by averaging the threshold at 500, 1000 and
2000 Hz of both ears.
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